Myomo, Inc. (MYO)
NYSEAMERICAN: MYO · Real-Time Price · USD
0.798
-0.023 (-2.78%)
Apr 29, 2026, 1:15 PM EDT - Market open

Company Description

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally.

The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.

It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library.

In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach.

Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders.

The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran’s administration, and distributors.

Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

Myomo, Inc.
Myomo logo
Country United States
Founded 2004
IPO Date Jun 12, 2017
Industry Medical Devices
Sector Healthcare
Employees 195
CEO Paul Gudonis

Contact Details

Address:
45 Blue Sky Dr., Suite 101
Burlington, Massachusetts 01803
United States
Phone 617 996 9058
Website myomo.com

Stock Details

Ticker Symbol MYO
Exchange NYSEAMERICAN
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001369290
CUSIP Number 62857J201
ISIN Number US62857J2015
SIC Code 3842

Key Executives

Name Position
Paul R. Gudonis President, Chief Executive Officer and Chairman
David A. Henry Chief Financial Officer
Dr. Harry Kovelman M.D. Chief Medical Officer
Colin Anderson Global Director of Operations
Galina Shtivelman Senior Director of Human Resources
Micah J. Mitchell Chief Commercial Officer
Kathy Sawyers Senior Director of Clinical Outcomes
Malcolm G. Bock Vice President of Engineering and Product Strategy

Latest SEC Filings

Date Type Title
Apr 16, 2026 8-K Current Report
Apr 13, 2026 144 Filing
Mar 9, 2026 S-8 Securities to be offered to employees in employee benefit plans
Mar 9, 2026 10-K Annual Report
Mar 9, 2026 8-K Current Report
Feb 11, 2026 SCHEDULE 13G/A Filing
Dec 29, 2025 SCHEDULE 13D Filing
Dec 16, 2025 8-K Current Report
Nov 12, 2025 SCHEDULE 13G/A Filing
Nov 10, 2025 10-Q Quarterly Report